Standardized Uptake Values Derived from F-FDG PET May Predict Lung Cancer Microvessel Density and Expression of KI 67, VEGF, and HIF-1 but Not Expression of Cyclin D1, PCNA, EGFR, PD L1, and P53

Overview

Journal Contrast Media Mol Imaging

Specialty Radiology

Date 2018 Jul 10

PMID 29983647

Citations 14

Authors

Alexey Surov

Hans Jonas Meyer

Andreas Wienke

Affiliations

Soon will be listed here.

Abstract

Background: Our purpose was to provide data regarding relationships between F-FDG PET and histopathological parameters in lung cancer.

Methods: MEDLINE library was screened for associations between PET parameters and histopathological features in lung cancer up to December 2017. Only papers containing correlation coefficients between PET parameters and histopathological findings were acquired for the analysis. Overall, 40 publications were identified.

Results: Associations between SUV and KI 67 were reported in 23 studies (1362 patients). The pooled correlation coefficient was 0.44. In 2 studies (180 patients), relationships between SUV and expression of cyclin D1 were analyzed (pooled correlation coefficient = 0.05). Correlation between SUV and HIF-1 was investigated in 3 studies (288 patients), and the pooled correlation coefficient was 0.42. In 5 studies (310 patients), associations between SUV and MVD were investigated (pooled correlation coefficient = 0.54). In 6 studies (305 patients), relationships between SUV and p53 were analyzed (pooled correlation coefficient = 0.30). In 6 studies (415 patients), associations between SUV and VEGF expression were investigated (pooled correlation coefficient = 0.44). In 5 studies (202 patients), associations between SUV and PCNA were investigated (pooled correlation coefficient = 0.32). In 3 studies (718 patients), associations between SUV and expression of PD L1 were analyzed (pooled correlation coefficient = 0.36). Finally, in 5 studies (409 patients), associations between SUV and EGFR were investigated (pooled correlation coefficient = 0.38).

Conclusion: SUV may predict microvessel density and expression of VEGF, KI 67, and HIF-1 in lung cancer.

Citing Articles

[Construction of A Nomogram Prediction Model for PD-L1 Expression  in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].

Hao L, Wang L, Zhang M, Yan J, Zhang F Zhongguo Fei Ai Za Zhi. 2023; 26(11):833-842.

PMID: 38061885 PMC: 10714048. DOI: 10.3779/j.issn.1009-3419.2023.101.32.

Immune checkpoint inhibition: a future guided by radiology.

Khan F, Jones K, Lyon P Br J Radiol. 2023; 96(1147):20220565.

PMID: 36752570 PMC: 10321249. DOI: 10.1259/bjr.20220565.

Pretreatment Metabolic Parameters Measured by F-FDG PET to Predict the Pathological Treatment Response of HCC Patients Treated With PD-1 Inhibitors and Lenvatinib as a Conversion Therapy in BCLC Stage C.

Wang G, Zhang W, Chen J, Luan X, Wang Z, Wang Y Front Oncol. 2022; 12:884372.

PMID: 35719917 PMC: 9204225. DOI: 10.3389/fonc.2022.884372.

SOX12 Promotes Thyroid Cancer Cell Proliferation and Invasion by Regulating the Expression of POU2F1 and POU3F1.

Su Z, Bao W, Yang G, Liu J, Zhao B Yonsei Med J. 2022; 63(6):591-600.

PMID: 35619584 PMC: 9171662. DOI: 10.3349/ymj.2022.63.6.591.

Hypoxia in Lung Cancer Management: A Translational Approach.

Ancel J, Perotin J, Dewolf M, Launois C, Mulette P, Nawrocki-Raby B Cancers (Basel). 2021; 13(14).

PMID: 34298636 PMC: 8307602. DOI: 10.3390/cancers13143421.

References

Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higuchi T, Imai H . Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer. Cancer Sci. 2009; 100(4):753-8. PMC: 11158756. DOI: 10.1111/j.1349-7006.2008.01077.x. View

Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert A . Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer. 2004; 91(12):2018-25. PMC: 2409786. DOI: 10.1038/sj.bjc.6602233. View

Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino G . Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016; 43(11):1954-61. DOI: 10.1007/s00259-016-3425-2. View

Jiang H, Shao W, Zhao W . VEGF-C in non-small cell lung cancer: meta-analysis. Clin Chim Acta. 2013; 427:94-9. DOI: 10.1016/j.cca.2013.10.002. View

Murakami S, Saito H, Sakuma Y, Mizutani Y, Ishikawa Y, Kondou T . Correlation of 18F-fluorodeoxyglucose uptake on positron emission tomography with Ki-67 index and pathological invasive area in lung adenocarcinomas 30 mm or less in size. Eur J Radiol. 2009; 75(2):e62-6. DOI: 10.1016/j.ejrad.2009.11.020. View

Liao S, Penney B, Wroblewski K, Zhang H, Simon C, Kampalath R . Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011; 39(1):27-38. DOI: 10.1007/s00259-011-1934-6. View

Zhang L, Jiang F, Xu L, Wang J, Bai J, Yin R . The role of cyclin D1 expression and patient's survival in non-small-cell lung cancer: a systematic review with meta-analysis. Clin Lung Cancer. 2011; 13(3):188-95. DOI: 10.1016/j.cllc.2011.10.003. View

Wallerek S, Sorensen J . Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I-IIIA. Eur Respir Rev. 2015; 24(136):340-55. PMC: 9487808. DOI: 10.1183/16000617.00005814. View

Araz O, Demirci E, Yilmazel Ucar E, Calik M, Karaman A, Durur-Subasi I . Roles of Ki-67, p53, transforming growth factor-β and lysyl oxidase in the metastasis of lung cancer. Respirology. 2014; 19(7):1034-9. DOI: 10.1111/resp.12345. View

10.

Park S, Lee E, Rhee S, Cho J, Choi S, Lee S . Correlation between Semi-Quantitative (18)F-FDG PET/CT Parameters and Ki-67 Expression in Small Cell Lung Cancer. Nucl Med Mol Imaging. 2016; 50(1):24-30. PMC: 4762859. DOI: 10.1007/s13139-015-0363-z. View

11.

Takada K, Toyokawa G, Okamoto T, Baba S, Kozuma Y, Matsubara T . Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on F-fluorodeoxyglucose positron emission tomography/computed tomography. Cancer Med. 2017; 6(11):2552-2561. PMC: 5673920. DOI: 10.1002/cam4.1215. View

12.

Furukawa T, Miyata Y, Kushitani K, Mimae T, Tsutani Y, Takeshima Y . Association between [18F]-fluoro-2-deoxyglucose uptake and expressions of hypoxia-induced factor 1α and glucose transporter 1 in non-small cell lung cancer. Jpn J Clin Oncol. 2015; 45(12):1154-61. DOI: 10.1093/jjco/hyv138. View

13.

Singhal S, Vachani A, Antin-Ozerkis D, Kaiser L, Albelda S . Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res. 2005; 11(11):3974-86. DOI: 10.1158/1078-0432.CCR-04-2661. View

14.

Surov A, Meyer H, Wienke A . Associations between apparent diffusion coefficient (ADC) and KI 67 in different tumors: a meta-analysis. Part 1: ADC. Oncotarget. 2017; 8(43):75434-75444. PMC: 5650434. DOI: 10.18632/oncotarget.20406. View

15.

Yamamoto Y, Nishiyama Y, Ishikawa S, Nakano J, Chang S, Bandoh S . Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007; 34(10):1610-6. DOI: 10.1007/s00259-007-0449-7. View

16.

Tsao M, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A . Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007; 25(33):5240-7. DOI: 10.1200/JCO.2007.12.6953. View

17.

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

18.

Surov A, Meyer H, Wienke A . Correlation between apparent diffusion coefficient (ADC) and cellularity is different in several tumors: a meta-analysis. Oncotarget. 2017; 8(35):59492-59499. PMC: 5601748. DOI: 10.18632/oncotarget.17752. View

19.

Leeflang M, Deeks J, Gatsonis C, Bossuyt P . Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008; 149(12):889-97. PMC: 2956514. DOI: 10.7326/0003-4819-149-12-200812160-00008. View

20.

Shibata H, Nomori H, Uno K, Iyama K, Tomiyoshi K, Nakashima R . 11C-acetate for positron emission tomography imaging of clinical stage IA lung adenocarcinoma: comparison with 18F-fluorodeoxyglucose for imaging and evaluation of tumor aggressiveness. Ann Nucl Med. 2009; 23(7):609-16. DOI: 10.1007/s12149-009-0278-9. View